Rituximab for acute demyelinating myelopathy after allogeneic hematopoietic stem cell transplantation: a case report. Issue 5 (3rd July 2020)

• Record Type: Journal Article
• Authors: Xing, Lina; Wen, Shupeng; Niu, Zhiyun; Wang, Fuxu; Zhang, Xuejun
• Is Part Of: Postgraduate medicine. Volume 132:Issue 5(2020)
• Page Start: 485
• Page End: 488
• Publication Date: 2020-07-03
• Subjects: Hematopoietic stem cell transplantation -- leukemia -- acute demyelinating myelopathy -- rituximab; Medicine -- Periodicals; Medicine -- Periodicals; Medicine; Periodicals; 610.5
• DOI: 10.1080/00325481.2020.1736884
• Languages: English
• ISSNs: 0032-5481

Abstract

ABSTRACT: Acute demyelinating myelopathy after allogeneic hematopoietic stem cell transplantation (HSCT) is rare, and the exact pathogenesis remains unclear. Here, we report the case of a 20-year-old patient with B-cell acute lymphocyte leukemia (B-ALL) who developed acute demyelinating myelopathy approximately 10 months after HSCT. Magnetic resonance imaging revealed high T2 signal intensity lesions from the C2-T4 levels of the spinal cord. Treatments with high doses of corticosteroids, immunoglobulins, and rituximab improved his neurologic symptoms, and he achieved 44 months of leukemia-free and graft-versus-host disease (GVHD)-free survival, with no recurrence of the demyelination myelopathy. An understanding of the contribution of immune reconstitution to the pathogenesis of demyelinating myelopathy after HSCT and the association of this disease with GVHD will require more clinical cases.